Abstract
BACKGROUND: Calprotectin is recognized as a promising prognostic as well as a diagnostic marker of cardiac disorders. In the present study, we aimed to survey the efficiency of serum calprotectin levels in anticipating the severity of coronary artery disease (CAD) along with in-hospital major adverse cardiovascular events (MACE) in patients with ST-segment elevation (STEMI) underlying primary percutaneous coronary intervention (PCI). MATERIALS AND METHODS: A total of 97 patients with STEMI participated and were evaluated for in-hospital MACE for possible correlation with serum calprotectin. RESULTS: Increased levels of serum calprotectin showed positive and negative correlation with severity of coronary arteries and left ventricular ejection fraction (LVEF) of STEMI patients, respectively. Regarding in-hospital MACE, only arrhythmia showed a significant relationship in patients with high calprotectin levels. CONCLUSION: High calprotectin levels may be a prognostic marker for occluded artery and LVEF in STEMI patients.